Rich-blood-platelet plasma preparation method without exogenous additives

Abstract

The invention relates to a rich-blood-platelet plasma preparation method without exogenous additives. The rich-blood-platelet plasma preparation method comprises the following steps of sample preparation: adding venous blood whole blood into a precooled centrifugal tube; primary centrifugation: performing primary centrifugation on 180g of venous blood whole blood for 10 minutes; secondary centrifugation: transferring 1550g of plasma layers into a novel centrifugal tube and performing trimming and secondary centrifugation for 10 minutes; abandoning the plasma supernate after the centrifugation; remaining the plasma supernate accounting for 1 / 10 of the venous blood whole blood volume; performing resuspension and thrombocyte precipitation; preparing and obtaining the rich-blood-platelet plasma, wherein all operations are performed at low temperature. The blood anticoagulation and blood platelet activation are regulated through physical temperature control; the addition of anticoagulants and coagulants is avoided; the clinic untoward effect caused by the addition of exogenous materials is avoided; the clinic use safety of the rich-blood-platelet plasma is ensured.

Description

technical field [0001] The invention belongs to the technical field of blood products, and relates to a method for preparing platelet-rich plasma without exogenous additives. Background technique [0002] Platelet-rich plasma (Platelet-rich plasma, PRP) specifically refers to autologous plasma containing 4-5 times the normal human platelet concentration. Platelets are cytoplasmic fragments of megakaryocytes, a category of white blood cells, formed in the bone marrow. They lack a nucleus, but contain organelles, as well as structures such as mitochondria, microtubules, and alpha, delta, and lambda particles. Among them, α-granules contain a variety of growth factors, including: platelet-derived growth factor (PDGF), epidermal growth factor (EGF), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), transforming growth factor ( TGF-β) and so on. PDGF can promote macrophage activation and angiogenesis, promote fibroblast proliferation activity and chemo...

AI Technical Summary

Problems solved by technology

[0004] Although the PRP prepared by the prior art has certain clinical application value, the exogenous additives such as anticoagulants and coagulants still have defects to a certain extent, such as: 1) sodium citrate can cause platelet aggregation At the same time, it will destroy platelets to a certain extent, thereby affecting the platelet count, and it is impossible to accurately obtain PRP with clinical significance. Calcium decreases, thereby showing tetany, bleeding tendency, blood pressure drop, slow heart rate and even cardiac arrest; 2) adverse reactions of thrombin, the concentration of thrombin in vitro can affect cell proliferation, tissue factor and inflammatory factor release, high It has neurotoxicity at high concentrations, inhibits cell proliferation, and even causes brain cell death

Images